-
It is not easy for domestic new drugs to go overseas, this pharmaceutical company initiated another breakthrough!
Time of Update: 2022-08-15
It is not easy for domestic new drugs to go overseas In March this year, Innovent announced that the “going overseas” had failed, and the marketing application of its core product sintilimab was not approved by the US FDA .
-
The pharmaceutical industry is facing a big shock!
Time of Update: 2022-08-15
. For example, some time ago, Sihuan Pharmaceutical announced that it plans to propose to sell some or all of its generic drugs and other non-core traditional medicine businesses that have not met performance expectations or long-term strategic goals due to the impact of changes in the pharmaceutical industry and policies.
-
The State Food and Drug Administration took multiple measures to encourage innovation, and the review and approval of children's drugs continued to maintain a growth momentum
Time of Update: 2022-08-15
At present, the "Regulations on the Implementation of the Drug Administration Law of the People's Republic of China (Draft for Comments)" organized by the State Food and Drug Administration is being
-
The New Deal is here, and the biopharmaceutical equipment industry is welcome!
Time of Update: 2022-08-15
"Enhancing the supply chain security level of high-end biopharmaceutical products and equipment" has been written into the "14th Five-Year Plan for Bioeconomic Development".
"Enhancing the supply chain security level of high-end biopharmaceutical products and equipment" has been written into the "14th Five-Year Plan for Bioeconomic Development".
-
The eve of bid opening!
Time of Update: 2022-08-15
The criteria for determining the companies to be selected in this centralized procurement continue the previous principle of price reduction (see Scenario 1 below), but the specific rules are more detailed (see Scenario 2 below) .
-
The Center for Drug Evaluation of the State Food and Drug Administration released the "Annual Report on the Progress of New Drug Registration Clinical Trials in China (2021)"
Time of Update: 2022-08-15
pdf In order to fully grasp the progress of clinical trials for new drug registration in China, use information technology to improve drug supervision capabilities, disclose clinical trial progress information in a timely manner, and provide reference for new drug research and development, resource allocation, and drug review and approval, the Center for Drug Evaluation is based on the registration and approval of drug clinical trials.
-
Antibody research and development change?
Time of Update: 2022-08-15
Big Molecule Popular Tracks Platform differentiation stimulates potential Whether it is from the technical iteration path of overseas pharmaceutical companies or the development process of domestic macromolecular drugs in China, the most common summary of antibody drug research and development is undoubtedly "monoantibodies look at the target, non-mabone look at the platform", which is also highly summarized The important value of the innovative technology platform in the upgrading of antibody R&D technology .
-
Announcement on the Draft Standard of Nitrogen and Calcium Carbonate Pharmaceutical Excipients
Time of Update: 2022-08-15
pdf The State Pharmacopoeia Committee plans to formulate standards for pharmaceutical excipients of nitrogen and calcium carbonate.
pdf The State Pharmacopoeia Committee plans to formulate standards for pharmaceutical excipients of nitrogen and calcium carbonate.
-
Alarm bells ring again!
Time of Update: 2022-08-15
According to relevant laws and regulations, the Henan Provincial Food and Drug Administration issued a warning to the company and fined 160,000 yuan .
According to relevant laws and regulations, the Henan Provincial Food and Drug Administration issued a warning to the company and fined 160,000 yuan .
-
A large number of enterprises take the initiative to cancel the "Medical Device Registration Certificate"!
Time of Update: 2022-08-15
[Pharmaceutical Network Industry News] On August 2, the State Food and Drug Administration announced that in accordance with the relevant provisions of the "Regulations on the Supervision and Administration of Medical Devices", according to the application of enterprises, the registration certificates of medical devices for 6 products are now cancelled .
-
A batch of medical device registration certificates have been cancelled!
Time of Update: 2022-08-15
On April 21, the Henan Provincial Drug Administration issued an announcement (No. 46, 2022) on the cancellation of the registration certificate of medical device products, stating that in accordance with the "Regulations on the Supervision and Administration of Medical Devices", according to the application of the enterprise, Yuan (Henan) is now cancelled.
-
Shionogi over $480 million to help develop new antifungal drug
Time of Update: 2022-08-12
Recently, Shionogi and F2G announced a strategic collaboration to develop and commercialize olorofim, a novel antifungal drug for the treatment of invasive fungal infections, in Europe and Asia .
-
How do you see the pharmaceutical sector in the second quarter?
Time of Update: 2022-08-12
” Click to enter the exhibition pageIn the first quarter, the pharmaceutical sector experienced successive declines and new shares broke out .
” Click to enter the exhibition pageIn the first quarter, the pharmaceutical sector experienced successive declines and new shares broke out .
-
The "14th Five-Year" National Health Plan focuses on the high-quality development of traditional Chinese medicine
Time of Update: 2022-08-12
The "14th Five-Year" National Health Plan issued by the General Office of the State Council recently proposed to promote the inheritance, innovation and development of traditional Chinese medicine, g
-
Innovative therapy dasiglucagon for congenital hyperinsulinemia reaches phase 3 clinical endpoint
Time of Update: 2022-08-12
Today, Zealand Pharma announced positive top-line results from a Phase 3 clinical trial of its glucagon analog dasiglucagon in pediatric patients with congenital hyperinsulinemia (CHI) .
html Today, Zealand Pharma announced positive top-line results from a Phase 3 clinical trial of its glucagon analog dasiglucagon in pediatric patients with congenital hyperinsulinemia (CHI) .
-
R&D investment of 12 pharmaceutical companies accounts for more than 10% of revenue
Time of Update: 2022-08-12
According to incomplete statistics in the industry, a total of 247 pharmaceutical companies in the two cities have invested more than 100 million yuan in R&D, including BeiGene, Hengrui Medicine, Fosun Pharma, China Biopharmaceuticals, CSPC, Innovent Bio, Junshi Bio, etc.
-
50 million yuan invested in semiconductors!
Time of Update: 2022-08-12
Recently, Buchang Pharmaceutical announced that it plans to invest 50 million yuan to invest in Suzhou Yuanhepu Huazhixin Equity Investment Partnership (Limited Partnership) (hereinafter referred to as "Intelligent Fund") .
-
There are many variables in the cooperation of new drug research and development, and many pharmaceutical companies have terminated the cooperation agreement
Time of Update: 2022-08-12
Recently, Bayer decided to terminate the US$670 million cooperation agreement with Atara for next-generation mesothelin-directed CAR-T cell therapy based on new evaluation data released .
Recently, Bayer decided to terminate the US$670 million cooperation agreement with Atara for next-generation mesothelin-directed CAR-T cell therapy based on new evaluation data released .
-
Bian Que's medical book written by Sima Qian will be published to include 106 lost medical prescriptions
Time of Update: 2022-08-12
[Concurrent] Liu Changhua, Director of the Research Institute of Chinese Unearthed Medical Documents and Cultural Relics, Chengdu University of Traditional Chinese Medicine Because what (Tianhui Medical Slips) shows us is more traditional, older, and more primitive, such documents .
-
On May 20, a number of pharmaceutical companies were "confessed", and the net purchase amount of financing exceeded 100 million yuan
Time of Update: 2022-08-12
In addition to Shanghai Pharmaceuticals, the top pharmaceutical stocks in terms of financing net purchases on the day include Huahai Pharmaceutical, Junshi Bio and other stocks, with net purchases exceeding 100 million yuan.
